Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) achieved its Phase III MAVERIC trial enrollment target of 110 patients ahead of schedule. The company plans to expand enrollment to up to 150 patients to strengthen the assessment of CardiolRx™'s efficacy in treating recurrent pericarditis. Topline results are now expected in mid-2027, with sufficient capital to fund the trial completion and a cash runway into Q1 2028.
How this was made
The 30-second read
Why it matters
The early enrollment hit and trial expansion improve statistical power, likely supporting the share price ahead of the mid‑2027 readout, while cash runway remains sufficient.
Market read
First‑report of trial enrollment success; material for biotech investors and may influence peer valuations.
What to watch
Potential regulatory or safety issues could emerge in the larger patient pool, dampening upside.
Background
Cardiol Therapeutics (NASDAQ: CRDL) is a late‑stage biotech developing anti‑inflammatory therapies for heart disease. The MAVERIC Phase III trial targets recurrent pericarditis.
Ticker impact
Cardiol Therapeutics announced it met its Phase III MAVERIC enrollment target early and will expand the trial to up to 150 patients, pushing topline results to mid‑2027.
moderate upside as investors price in improved trial power and delayed guidance
Biotech stocks typically rally on early enrollment success and trial expansion, especially when no new capital is needed.
Market effects
Positive signal for the pericarditis/heart‑disease biotech niche, may lift peer valuations.
Limited to US and Canadian biotech markets where Cardiol is listed.
Modest; primarily affects investors focused on late‑stage clinical‑trial biotech stocks.
Counterpoint
If the expanded enrollment delays data, the stock could face a longer wait and heightened risk.
Key entities
- companyCardiol Therapeutics Inc.
Late‑stage biotech developing CardiolRx™ for pericarditis.
- personDavid Elsley
President and CEO of Cardiol Therapeutics.
